Table 1.
Cohort characteristics.
| Characteristics | N = 757 |
|---|---|
| Demography | |
| Age (years), median (IQR) | 53 (45–60) |
| Male, n (%) | 565 (74.6) |
| Duration of therapy (weeks), median (IQR) | 159 (156–262) |
| Pretreatment ALT (median, IQR) | 115 (74–232) |
| Cirrhosis (n = 448), n (%) | 23 (5.1) |
| Ethnicity, n (%) | |
| Asian | 667 (88) |
| Caucasian | 70 (9.2) |
| Other | 20 (2.6) |
| Treatment, n (%) | |
| ETV | 428 (56.5) |
| TDF | 238 (31.4) |
| Other∗ | 91 (12.0) |
| HBV genotype (n = 629), n (%) | |
| A | 10 (1.6) |
| B | 349 (46.1) |
| C | 184 (24.3) |
| D | 63 (8.3) |
| Other | 23 (3.0) |
| Pretreatment HBV DNA, n (%) | |
| <20,000 IU/ml | 150 (20) |
| >20,000 IU/ml | 607 (80.2) |
| EOT HBsAg, n (%) | |
| <100 IU/ml | 200 (26.4) |
| >100 IU/ml | 557 (73.6) |
| EOT HBcrAg, n (%) | |
| Undetectable | 237 (31.3) |
| Detectable | 520 (68.7) |
ALT, alanine aminotransferase; EOT, end of treatment; ETV, entecavir; HBcrAg, hepatitis B core-related antigen; TDF, tenofovir.
∗
Lamivudine, telbivudine, or combination therapy.